雄激素剥夺疗法 (ADT) 已成为转移性前列腺癌 (PCa) 治疗的标准疗法；然而，ADT 具有必须解决的重大不良反应 (AE)。本次综述旨在强调减轻 ADT 不良事件的机会并探索 PCa 管理的替代方案。具体来说，我们讨论了减轻 ADT 不良事件的行为和药理学策略，以及针对激素敏感和去势抵抗性 PCa 的 ADT 节约方法。配备有效的缓解策略和可能的替代方案，临床医生和研究人员可以优化目前接受 ADT 治疗 PCa 的患者的健康相关生活质量，并考虑使患者免受 ADT AE 的治疗。

Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be addressed. This review aims to highlight opportunities to mitigate AEs of ADT and explore alternatives in PCa management. Specifically, we discuss behavioral and pharmacologic strategies for mitigating ADT AEs as well as ADT-sparing approaches for hormone-sensitive and castration-resistant PCa. Equipped with effective mitigation strategies and possible alternatives, clinicians and researchers can optimize health-related quality of life for patients currently receiving ADT for PCa and consider treatments that spare patients from AEs of ADT.